Spots Global Cancer Trial Database for sorafenib tosylate

Every month we try and update this database with for sorafenib tosylate cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.

The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.

Study title	NCT ID	Conditions	Interventions	Eligibility	Organization
Sorafenib in Treating Patients With Metastatic Kidney Cancer That Has Not Responded to Sunitinib or Bevacizumab	NCT00866320	Kidney Cancer	sorafenib tosyl...	18 Years -	Case Comprehensive Cancer Center
Sorafenib, Cetuximab, and Irinotecan in Treating Patients With Advanced or Metastatic Colorectal Cancer	NCT00134069	Recurrent Colon... Recurrent Recta... Stage III Colon... Stage III Recta... Stage IV Colon ... Stage IV Rectal...	sorafenib tosyl... cetuximab irinotecan hydr...	18 Years -	National Cancer Institute (NCI)
Study to Compare Selective Internal Radiation Therapy (SIRT) Versus Sorafenib in Locally Advanced Hepatocellular Carcinoma (HCC)	NCT01135056	Hepatocellular ...	SIR-Spheres Sorafenib tosyl...	18 Years -	Singapore General Hospital
Carboplatin and Paclitaxel With or Without Sorafenib Tosylate in Treating Patients With Stage III or Stage IV Melanoma That Cannot Be Removed by Surgery	NCT00110019	Mucosal Melanom... Recurrent Melan... Stage IIIA Skin... Stage IIIB Skin... Stage IIIC Skin... Stage IV Skin M...	Carboplatin Laboratory Biom... Paclitaxel Pharmacological... Placebo Sorafenib Tosyl...	18 Years -	National Cancer Institute (NCI)
Sorafenib Tosylate and Bevacizumab in Treating Patients With Advanced Kidney Cancer	NCT00126503	Chromophobe Ren... Clear Cell Rena... Papillary Renal... Recurrent Renal... Sarcomatoid Ren... Stage IV Renal ...	Bevacizumab Sorafenib Tosyl... Pharmacological... Laboratory Biom...	18 Years -	National Cancer Institute (NCI)
Sorafenib in Treating Patients With Stage IIIB or Stage IV Non-Small Cell Lung Cancer	NCT00098540	Recurrent Non-s... Stage IIIB Non-... Stage IV Non-sm...	sorafenib tosyl... laboratory biom...	18 Years -	National Cancer Institute (NCI)
Sorafenib in Treating Patients With Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Peritoneal Cancer in at Least the Second Remission	NCT00522301	Fallopian Tube ... Ovarian Cancer Primary Periton...	sorafenib tosyl... immunoenzyme te... immunohistochem... laboratory biom... pharmacological...	18 Years - 120 Years	Memorial Sloan Kettering Cancer Center
Bevacizumab and Sorafenib in Treating Patients With Unresectable Stage III or Stage IV Malignant Melanoma	NCT00387751	Recurrent Melan... Stage III Skin ... Stage IV Skin M...	Bevacizumab Laboratory Biom... Pharmacological... Sorafenib Tosyl...	18 Years - 120 Years	National Cancer Institute (NCI)
Sorafenib in Treating Patients With Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Peritoneal Cancer in at Least the Second Remission	NCT00522301	Fallopian Tube ... Ovarian Cancer Primary Periton...	sorafenib tosyl... immunoenzyme te... immunohistochem... laboratory biom... pharmacological...	18 Years - 120 Years	Memorial Sloan Kettering Cancer Center
Sorafenib With or Without Gemcitabine in Treating Patients With Metastatic Pancreatic Cancer	NCT00114244	Stage IV Pancre...	sorafenib tosyl... gemcitabine hyd... laboratory biom...	18 Years -	National Cancer Institute (NCI)
Sorafenib, Cetuximab, and Irinotecan in Treating Patients With Advanced or Metastatic Colorectal Cancer	NCT00134069	Recurrent Colon... Recurrent Recta... Stage III Colon... Stage III Recta... Stage IV Colon ... Stage IV Rectal...	sorafenib tosyl... cetuximab irinotecan hydr...	18 Years -	National Cancer Institute (NCI)
Panobinostat and Sorafenib in Treating Patients With Liver Cancer That is Metastatic and/or Cannot Be Removed by Surgery	NCT00873002	Liver Cancer	panobinostat sorafenib tosyl...	18 Years -	Case Comprehensive Cancer Center
Entinostat and Sorafenib Tosylate in Treating Patients With Advanced or Metastatic Solid Tumors or Refractory or Relapsed Acute Myeloid Leukemia	NCT01159301	Adult Acute Bas... Adult Acute Eos... Adult Acute Meg... Adult Acute Min... Adult Acute Mon... Adult Acute Mon... Adult Acute Mye... Adult Acute Mye... Adult Acute Mye... Adult Acute Mye... Adult Acute Mye... Adult Acute Mye... Adult Acute Mye... Adult Acute Mye... Adult Erythrole... Adult Pure Eryt... Blastic Phase C... Recurrent Adult... Unspecified Adu...	entinostat sorafenib tosyl... pharmacological... laboratory biom...	18 Years -	National Cancer Institute (NCI)
Sorafenib in Treating Patients With Malignant Gastrointestinal Stromal Tumor That Progressed During or After Previous Treatment With Imatinib Mesylate and Sunitinib Malate	NCT00265798	Gastrointestina...	Sorafenib Tosyl...	18 Years -	National Cancer Institute (NCI)
Vemurafenib With Sorafenib Tosylate or Crizotinib in Treating Patients With Advanced Malignancies With BRAF Mutations	NCT01531361	Advanced Malign... BRAF Gene Mutat... Metastatic Mali... Recurrent Malig... Refractory Mali...	Crizotinib Laboratory Biom... Pharmacological... Sorafenib Tosyl... Vemurafenib	18 Years -	M.D. Anderson Cancer Center
Sorafenib in Treating Patients With Metastatic or Unresectable Solid Tumors, Multiple Myeloma, or Non-Hodgkin's Lymphoma With or Without Impaired Liver or Kidney Function	NCT00118170	Extranodal Marg... Nodal Marginal ... Recurrent Adult... Recurrent Adult... Recurrent Adult... Recurrent Adult... Recurrent Adult... Recurrent Adult... Recurrent Adult... Recurrent Grade... Recurrent Grade... Recurrent Grade... Recurrent Mantl... Recurrent Margi... Recurrent Small... Refractory Mult... Splenic Margina... Stage II Multip... Stage III Adult... Stage III Adult... Stage III Adult... Stage III Adult... Stage III Adult... Stage III Adult... Stage III Grade... Stage III Grade... Stage III Grade... Stage III Mantl... Stage III Margi... Stage III Multi... Stage III Small... Stage IV Adult ... Stage IV Adult ... Stage IV Adult ... Stage IV Adult ... Stage IV Adult ... Stage IV Adult ... Stage IV Grade ... Stage IV Grade ... Stage IV Grade ... Stage IV Mantle... Stage IV Margin... Stage IV Small ... Unspecified Adu... Waldenström Mac...	sorafenib tosyl... pharmacological...	18 Years -	National Cancer Institute (NCI)
Sorafenib in Treating Patients With Metastatic or Recurrent Prostate Cancer	NCT00093457	Prostate Cancer	sorafenib tosyl...	18 Years - 120 Years	Canadian Cancer Trials Group
S0420, Sorafenib in Treating Patients With Recurrent or Metastatic Head and Neck Cancer	NCT00096512	Metastatic Squa... Recurrent Metas... Recurrent Saliv... Recurrent Squam... Recurrent Squam... Recurrent Squam... Recurrent Squam... Recurrent Squam... Recurrent Squam... Recurrent Verru... Recurrent Verru... Salivary Gland ... Stage IV Squamo... Stage IV Squamo... Stage IVA Saliv... Stage IVA Squam... Stage IVA Squam... Stage IVA Squam... Stage IVA Squam... Stage IVA Verru... Stage IVA Verru... Stage IVB Saliv... Stage IVB Squam... Stage IVB Squam... Stage IVB Squam... Stage IVB Squam... Stage IVB Verru... Stage IVB Verru... Stage IVC Saliv... Stage IVC Squam... Stage IVC Squam... Stage IVC Squam... Stage IVC Squam... Stage IVC Verru... Stage IVC Verru... Tongue Cancer Untreated Metas...	sorafenib tosyl... laboratory biom...	18 Years -	National Cancer Institute (NCI)
Sorafenib, Epirubicin, Ifosfamide, and Radiation Therapy Followed By Surgery in Treating Patients With High-Risk Stage II or Stage III Soft Tissue Sarcoma	NCT00822848	Sarcoma	epirubicin hydr... ifosfamide sorafenib tosyl... immunoenzyme te... immunohistochem... laboratory biom... adjuvant therap... neoadjuvant the... therapeutic con... hypofractionate...	15 Years - 120 Years	OHSU Knight Cancer Institute
Trebananib With or Without Bevacizumab, Pazopanib Hydrochloride, Sorafenib Tosylate, or Sunitinib Malate in Treating Patients With Advanced Kidney Cancer	NCT01664182	Advanced Renal ... Advanced Sarcom... Stage III Renal... Stage IV Renal ...	Bevacizumab Pazopanib Hydro... Sorafenib Tosyl... Sunitinib Malat... Trebananib	18 Years -	National Cancer Institute (NCI)
Temozolomide and Sorafenib in Treating Patients With Metastatic or Unresectable Melanoma	NCT00602576	Melanoma (Skin)	sorafenib tosyl... temozolomide	18 Years - 120 Years	Abramson Cancer Center at Penn Medicine
Chinese Herbal Formulation PHY906 and Sorafenib Tosylate in Treating Patients With Advanced Liver Cancer	NCT01666756	Adult Primary H... Advanced Adult ... Advanced Adult ... BCLC Stage B Ad... BCLC Stage C Ad...	Chinese herbal ... sorafenib tosyl... laboratory biom... pharmacological...	18 Years -	City of Hope Medical Center
External-Beam Radiation Therapy, Capecitabine, and Sorafenib in Treating Patients With Locally Advanced Rectal Cancer	NCT00869570	Colorectal Canc...	capecitabine sorafenib tosyl... radiation thera...	18 Years - 120 Years	Swiss Group for Clinical Cancer Research
Sorafenib in Treating Patients With Refractory or Relapsed Acute Leukemia, Myelodysplastic Syndromes, or Blastic Phase Chronic Myelogenous Leukemia	NCT00217646	Adult Acute Bas... Adult Acute Eos... Adult Acute Meg... Adult Acute Mon... Adult Acute Mon... Adult Acute Mye... Adult Acute Mye... Adult Acute Mye... Adult Acute Mye... Adult Acute Mye... Adult Acute Mye... Adult Acute Mye... Adult Acute Mye... Adult Acute Pro... Adult Erythrole... Adult Pure Eryt... Alkylating Agen... Blastic Phase de Novo Myelody... Previously Trea... Recurrent Adult... Recurrent Adult... Secondary Acute... Secondary Myelo...	Sorafenib Tosyl...	18 Years -	National Cancer Institute (NCI)
Sorafenib Tosylate and Gemcitabine Hydrochloride in Treating Patients With Recurrent Epithelial Ovarian Cancer	NCT00096395	Recurrent Ovari... Recurrent Prima...	gemcitabine hyd... sorafenib tosyl... laboratory biom...	18 Years -	National Cancer Institute (NCI)
Sorafenib and Docetaxel in Patients With Prostate Cancer That Did Not Respond to Previous Hormone Therapy	NCT00589420	Prostate Cancer	docetaxel sorafenib tosyl...	18 Years - 120 Years	Abramson Cancer Center at Penn Medicine
Sorafenib With Either Temsirolimus or Tipifarnib in Treating Patients With Stage IV Malignant Melanoma That Cannot Be Removed By Surgery	NCT00281957	Recurrent Melan... Stage IV Melano...	sorafenib tosyl... tipifarnib temsirolimus	18 Years -	National Cancer Institute (NCI)
Sorafenib Tosylate, Bevacizumab, Irinotecan Hydrochloride, Leucovorin Calcium, and Fluorouracil in Treating Patients With Metastatic Colorectal Cancer	NCT01383343	Recurrent Colon... Recurrent Recta... Stage IVA Colon... Stage IVA Recta... Stage IVB Colon... Stage IVB Recta...	Bevacizumab Fluorouracil Irinotecan Hydr... Leucovorin Calc... Sorafenib Tosyl...	18 Years -	National Cancer Institute (NCI)
Sorafenib and Fulvestrant in Treating Patients With Locally Advanced or Metastatic Breast Cancer That Did Not Respond to Aromatase Inhibitor Therapy	NCT00722072	Breast Cancer	fulvestrant sorafenib tosyl...	18 Years - 120 Years	OHSU Knight Cancer Institute
Sorafenib in Treating Patients With Extensive Stage Small Cell Lung Cancer	NCT00182689	Extensive Stage... Recurrent Small...	sorafenib tosyl...	18 Years -	National Cancer Institute (NCI)
Sorafenib in Treating Patients With Metastatic or Unresectable Solid Tumors, Multiple Myeloma, or Non-Hodgkin's Lymphoma With or Without Impaired Liver or Kidney Function	NCT00118170	Extranodal Marg... Nodal Marginal ... Recurrent Adult... Recurrent Adult... Recurrent Adult... Recurrent Adult... Recurrent Adult... Recurrent Adult... Recurrent Adult... Recurrent Grade... Recurrent Grade... Recurrent Grade... Recurrent Mantl... Recurrent Margi... Recurrent Small... Refractory Mult... Splenic Margina... Stage II Multip... Stage III Adult... Stage III Adult... Stage III Adult... Stage III Adult... Stage III Adult... Stage III Adult... Stage III Grade... Stage III Grade... Stage III Grade... Stage III Mantl... Stage III Margi... Stage III Multi... Stage III Small... Stage IV Adult ... Stage IV Adult ... Stage IV Adult ... Stage IV Adult ... Stage IV Adult ... Stage IV Adult ... Stage IV Grade ... Stage IV Grade ... Stage IV Grade ... Stage IV Mantle... Stage IV Margin... Stage IV Small ... Unspecified Adu... Waldenström Mac...	sorafenib tosyl... pharmacological...	18 Years -	National Cancer Institute (NCI)
Sorafenib and Temsirolimus in Treating Patients With Metastatic, Recurrent, or Unresectable Melanoma	NCT01851408	Melanoma Recurrent Melan... Stage III Melan... Stage IV Melano...	sorafenib tosyl... temsirolimus	18 Years -	National Cancer Institute (NCI)
Sorafenib Tosylate, Cisplatin, and Docetaxel in Treating Patients With Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck	NCT02035527	Metastatic Squa... Recurrent Metas... Recurrent Saliv... Recurrent Squam... Recurrent Squam... Recurrent Squam... Recurrent Squam... Recurrent Squam... Recurrent Squam... Recurrent Verru... Recurrent Verru... Salivary Gland ... Stage IV Squamo... Stage IV Squamo... Stage IVA Saliv... Stage IVA Squam... Stage IVA Oral ... Stage IVA Squam... Stage IVA Squam... Stage IVA Verru... Stage IVA Verru... Stage IVB Saliv... Stage IVB Squam... Stage IVB Squam... Stage IVB Squam... Stage IVB Squam... Stage IVB Verru... Stage IVB Verru... Stage IVC Saliv... Stage IVC Squam... Stage IVC Squam... Stage IVC Squam... Stage IVC Squam... Stage IVC Verru... Stage IVC Verru... Tongue Cancer Untreated Metas...	sorafenib tosyl... cisplatin docetaxel Correlative Stu...	18 Years -	Ohio State University Comprehensive Cancer Center
Sorafenib in Treating Patients With Advanced Anaplastic Thyroid Cancer	NCT00126568	Anaplastic Thyr... Recurrent Thyro...	sorafenib tosyl...	18 Years -	National Cancer Institute (NCI)
Sorafenib and Anastrozole in Treating Postmenopausal Women With Metastatic Breast Cancer	NCT00217399	Recurrent Breas... Stage IV Breast...	sorafenib tosyl... anastrozole	18 Years -	National Cancer Institute (NCI)
Pre-operative Administration of Sorafenib in Patients With Metastatic Renal Cell Carcinoma Undergoing Kidney Removal	NCT00480389	Renal Cell Carc... Metastatic Dise...	Sorafenib	18 Years -	University Health Network, Toronto
Sorafenib Tosylate and Everolimus in Treating Patients With Advanced Solid Tumors and Metastatic Pancreatic Cancer That Does Not Respond to Gemcitabine Hydrochloride	NCT00981162	Acinar Cell Ade... Duct Cell Adeno... Recurrent Pancr... Stage IV Pancre... Unspecified Adu...	sorafenib tosyl... everolimus laboratory biom... pharmacogenomic... pharmacological...	18 Years -	Roswell Park Cancer Institute
Sunitinib Malate or Sorafenib Tosylate in Treating Patients With Kidney Cancer That Was Removed By Surgery	NCT00326898	Clear Cell Rena... Stage I Renal C... Stage II Renal ... Stage III Renal...	Laboratory Biom... Placebo Quality-of-Life... Sorafenib Tosyl... Sunitinib Malat...	18 Years -	National Cancer Institute (NCI)
Sorafenib Tosylate With or Without Recombinant Interferon Alfa-2b in Treating Patients With Metastatic Kidney Cancer	NCT00126594	Clear Cell Rena... Recurrent Renal... Stage IV Renal ...	Sorafenib Tosyl... Recombinant Int... Laboratory Biom...	18 Years -	National Cancer Institute (NCI)
Sorafenib and Bevacizumab in Treating Patients With Metastatic Colorectal Cancer	NCT00826540	Recurrent Colon... Recurrent Recta... Stage IV Colon ... Stage IV Rectal...	sorafenib tosyl... bevacizumab	18 Years -	Alliance for Clinical Trials in Oncology
Sorafenib in Treating Patients With Regional or Metastatic Cancer of the Urothelium	NCT00112905	Adenocarcinoma ... Distal Urethral... Metastatic Tran... Proximal Urethr... Recurrent Bladd... Recurrent Trans... Recurrent Ureth... Regional Transi... Squamous Cell C... Stage III Bladd... Stage IV Bladde... Transitional Ce... Urethral Cancer...	sorafenib tosyl... laboratory biom...	18 Years -	National Cancer Institute (NCI)
Sorafenib in Treating Patients With Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Peritoneal Cancer in at Least the Second Remission	NCT00522301	Fallopian Tube ... Ovarian Cancer Primary Periton...	sorafenib tosyl... immunoenzyme te... immunohistochem... laboratory biom... pharmacological...	18 Years - 120 Years	Memorial Sloan Kettering Cancer Center
Sorafenib and Bevacizumab in Treating Patients With Metastatic Colorectal Cancer	NCT00826540	Recurrent Colon... Recurrent Recta... Stage IV Colon ... Stage IV Rectal...	sorafenib tosyl... bevacizumab	18 Years -	Alliance for Clinical Trials in Oncology
Bevacizumab and Erlotinib or Sorafenib as First-Line Therapy in Treating Patients With Advanced Liver Cancer	NCT00881751	Liver Cancer	bevacizumab erlotinib hydro... sorafenib tosyl...	18 Years - 116 Years	Medical University of South Carolina
Sorafenib and Gemcitabine in Treating Patients With Locally Advanced or Metastatic Pancreatic Cancer	NCT00095966	Adenocarcinoma ... Recurrent Pancr... Stage II Pancre... Stage III Pancr... Stage IV Pancre...	sorafenib tosyl... gemcitabine hyd...	18 Years -	National Cancer Institute (NCI)
Sorafenib With or Without Gemcitabine in Treating Patients With Metastatic Pancreatic Cancer	NCT00114244	Stage IV Pancre...	sorafenib tosyl... gemcitabine hyd... laboratory biom...	18 Years -	National Cancer Institute (NCI)
Sorafenib Tosylate Following a Liver Transplant in Treating Patients With Liver Cancer	NCT01624285	Adult Primary H... Localized Resec... Localized Unres... Recurrent Adult...	sorafenib tosyl... placebo laboratory biom...	19 Years -	Jonsson Comprehensive Cancer Center
Sorafenib and Temsirolimus in Treating Patients With Metastatic, Recurrent, or Unresectable Melanoma	NCT00349206	Melanoma Recurrent Melan... Stage III Melan... Stage IV Melano...	sorafenib tosyl... temsirolimus	18 Years -	National Cancer Institute (NCI)
Phase 2b Study of Taxol Plus Sorafenib or Placebo in Patients With Advanced Breast Cancer	NCT00499525	Breast Cancer	paclitaxel sorafenib tosyl... placebo	18 Years - 120 Years	Northwestern University
Sorafenib, Lenalidomide, and Dexamethasone in Treating Patients With Relapsed or Refractory Multiple Myeloma	NCT00687674	Multiple Myelom...	dexamethasone sorafenib tosyl... Lenalidomide	18 Years - 120 Years	Mayo Clinic
Navitoclax and Sorafenib Tosylate in Treating Patients With Relapsed or Refractory Solid Tumors	NCT02143401	Cirrhosis Hepatitis B Inf... Hepatitis C Inf... Metastatic Mali... Recurrent Hepat... Recurrent Malig... Refractory Mali... Stage IV Hepato... Unresectable So...	Laboratory Biom... Navitoclax Pharmacological... Sorafenib Sorafenib Tosyl...	18 Years -	National Cancer Institute (NCI)
Sorafenib in Treating Patients With Regional or Metastatic Cancer of the Urothelium	NCT00112905	Adenocarcinoma ... Distal Urethral... Metastatic Tran... Proximal Urethr... Recurrent Bladd... Recurrent Trans... Recurrent Ureth... Regional Transi... Squamous Cell C... Stage III Bladd... Stage IV Bladde... Transitional Ce... Urethral Cancer...	sorafenib tosyl... laboratory biom...	18 Years -	National Cancer Institute (NCI)
Sorafenib Combined With Cisplatin and Etoposide or Carboplatin and Pemetrexed in Treating Patients With Metastatic Solid Tumors	NCT00573690	Unspecified Adu...	carboplatin cisplatin etoposide pemetrexed diso... sorafenib tosyl...	18 Years -	UNC Lineberger Comprehensive Cancer Center
Sorafenib in Treating Patients Who Are Undergoing Surgery for Metastatic Kidney Cancer	NCT00126659	Clear Cell Rena... Recurrent Renal... Stage IV Renal ...	therapeutic con... sorafenib tosyl... laboratory biom...	18 Years -	National Cancer Institute (NCI)
Navitoclax and Sorafenib Tosylate in Treating Patients With Relapsed or Refractory Solid Tumors	NCT02143401	Cirrhosis Hepatitis B Inf... Hepatitis C Inf... Metastatic Mali... Recurrent Hepat... Recurrent Malig... Refractory Mali... Stage IV Hepato... Unresectable So...	Laboratory Biom... Navitoclax Pharmacological... Sorafenib Sorafenib Tosyl...	18 Years -	National Cancer Institute (NCI)
Sorafenib in Treating Patients With Refractory or Relapsed Acute Leukemia, Myelodysplastic Syndromes, or Blastic Phase Chronic Myelogenous Leukemia	NCT00217646	Adult Acute Bas... Adult Acute Eos... Adult Acute Meg... Adult Acute Mon... Adult Acute Mon... Adult Acute Mye... Adult Acute Mye... Adult Acute Mye... Adult Acute Mye... Adult Acute Mye... Adult Acute Mye... Adult Acute Mye... Adult Acute Mye... Adult Acute Pro... Adult Erythrole... Adult Pure Eryt... Alkylating Agen... Blastic Phase de Novo Myelody... Previously Trea... Recurrent Adult... Recurrent Adult... Secondary Acute... Secondary Myelo...	Sorafenib Tosyl...	18 Years -	National Cancer Institute (NCI)
Sorafenib Tosylate and Gemcitabine Hydrochloride in Treating Patients With Recurrent Epithelial Ovarian Cancer	NCT00096395	Recurrent Ovari... Recurrent Prima...	gemcitabine hyd... sorafenib tosyl... laboratory biom...	18 Years -	National Cancer Institute (NCI)
Sorafenib Tosylate, Bevacizumab, Irinotecan Hydrochloride, Leucovorin Calcium, and Fluorouracil in Treating Patients With Metastatic Colorectal Cancer	NCT01383343	Recurrent Colon... Recurrent Recta... Stage IVA Colon... Stage IVA Recta... Stage IVB Colon... Stage IVB Recta...	Bevacizumab Fluorouracil Irinotecan Hydr... Leucovorin Calc... Sorafenib Tosyl...	18 Years -	National Cancer Institute (NCI)
Bevacizumab and Sorafenib as First-Line Therapy in Treating Patients With Locally Advanced or Metastatic Liver Cancer	NCT00867321	Liver Cancer	bevacizumab sorafenib tosyl...	18 Years - 120 Years	Alliance for Clinical Trials in Oncology
Sorafenib Tosylate in Treating Patients With Liver Cancer Who Have Undergone a Liver Transplant	NCT00844168	Adult Primary H... Advanced Adult ... Localized Resec... Localized Unres... Recurrent Adult...	sorafenib tosyl... laboratory biom...	18 Years -	University of Washington
Sorafenib. ICORG 06-41, V4	NCT01158287	Esophageal Canc... Gastric Cancer	sorafenib tosyl... laboratory biom...	18 Years -	Cancer Trials Ireland
Phase II Randomized Trial of the Combination of Cetuximab and Sorafenib or Single Agent Cetuximab	NCT00939627	Metastatic Squa... Recurrent Metas... Recurrent Saliv... Recurrent Squam... Recurrent Squam... Recurrent Squam... Recurrent Squam... Recurrent Squam... Recurrent Squam... Recurrent Verru... Recurrent Verru... Salivary Gland ... Stage IV Squamo... Stage IV Squamo... Stage IVA Saliv... Stage IVA Squam... Stage IVA Squam... Stage IVA Squam... Stage IVA Squam... Stage IVA Verru... Stage IVA Verru... Stage IVB Saliv... Stage IVB Squam... Stage IVB Squam... Stage IVB Squam... Stage IVB Squam... Stage IVB Verru... Stage IVB Verru... Stage IVC Saliv... Stage IVC Squam... Stage IVC Squam... Stage IVC Squam... Stage IVC Squam... Stage IVC Verru... Stage IVC Verru... Tongue Cancer Untreated Metas...	cetuximab placebo sorafenib tosyl... laboratory biom... quality-of-life...	18 Years -	National Cancer Institute (NCI)
Personalized Kinase Inhibitor Therapy Combined With Chemotherapy in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia and Acute Lymphoblastic Leukemia	NCT02779283	Acute Lymphobla... Acute Myeloid L...	Cyclophosphamid... Cytarabine Dasatinib Dexamethasone Doxorubicin Hyd... Idarubicin Idelalisib In Vitro Kinase... Leucovorin Calc... Methotrexate Methylprednisol... Ponatinib Hydro... Rituximab Ruxolitinib Pho... Sorafenib Tosyl... Sunitinib Malat... Vincristine Sul...	18 Years - 64 Years	OHSU Knight Cancer Institute
Sorafenib in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, or Chronic Myelogenous Leukemia	NCT00131989	Adult Acute Bas... Adult Acute Eos... Adult Acute Meg... Adult Acute Min... Adult Acute Mon... Adult Acute Mye... Adult Acute Mye... Adult Acute Mye... Adult Acute Mye... Adult Acute Mye... Adult Acute Mye... Adult Acute Mye... Adult Acute Mye... Adult Erythrole... Adult Pure Eryt... Recurrent Adult... Recurrent Adult...	sorafenib tosyl... pharmacological... laboratory biom...	18 Years -	National Cancer Institute (NCI)
Sorafenib Tosylate and Temsirolimus in Treating Patients With Recurrent Glioblastoma	NCT00329719	Adult Glioblast... Adult Gliosarco... Recurrent Adult...	Conventional Su... Laboratory Biom... Sorafenib Tosyl... Temsirolimus	18 Years -	National Cancer Institute (NCI)
Sorafenib in Treating Patients With Malignant Gastrointestinal Stromal Tumor That Progressed During or After Previous Treatment With Imatinib Mesylate and Sunitinib Malate	NCT00265798	Gastrointestina...	Sorafenib Tosyl...	18 Years -	National Cancer Institute (NCI)
Sorafenib and Erlotinib in Treating Patients With Stage IIIB or Stage IV Non-Small Cell Lung Cancer That Has Not Responded to Chemotherapy	NCT00801385	Lung Cancer	erlotinib hydro... sorafenib tosyl... DNA analysis mutation analys... polymerase chai... protein analysi... protein express... immunohistochem... laboratory biom...	18 Years -	National Cancer Institute (NCI)
Sorafenib in Treating Young Patients With Relapsed or Refractory Solid Tumors or Leukemia	NCT01445080	Blastic Phase Childhood Acute... Childhood Chron... Childhood Solid... Chronic Myeloge... Juvenile Myelom... Philadelphia Ch... Recurrent Child... Recurrent Child... Recurrent Disea...	Laboratory Biom... Pharmacological... Sorafenib Tosyl...	2 Years - 21 Years	National Cancer Institute (NCI)
Sorafenib Combined With Erlotinib, Tipifarnib, or Temsirolimus in Treating Patients With Recurrent Glioblastoma Multiforme or Gliosarcoma	NCT00335764	Adult Giant Cel... Adult Glioblast... Adult Gliosarco... Recurrent Adult...	sorafenib tosyl... erlotinib hydro... tipifarnib temsirolimus	18 Years -	National Cancer Institute (NCI)
Pre-operative Administration of Sorafenib in Patients With Metastatic Renal Cell Carcinoma Undergoing Kidney Removal	NCT00480389	Renal Cell Carc... Metastatic Dise...	Sorafenib	18 Years -	University Health Network, Toronto
Sorafenib Tosylate and Hypoxia-Activated Prodrug TH-302 in Treating Patients With Advanced Kidney Cancer or Liver Cancer That Cannot Be Removed By Surgery	NCT01497444	Kidney Cancer Liver Cancer	hypoxia-activat... sorafenib tosyl...	18 Years -	Alliance for Clinical Trials in Oncology
Sorafenib in Treating Patients Undergoing Surgery for Stage II, Stage III, or Stage IV Kidney Cancer	NCT00405366	Kidney Cancer	sorafenib tosyl...	18 Years -	UNC Lineberger Comprehensive Cancer Center
Sorafenib Tosylate in Treating Patients With Metastatic, Locally Advanced, or Recurrent Medullary Thyroid Cancer	NCT00390325	Hereditary Thyr... Locally Advance... Multiple Endocr... Multiple Endocr... Recurrent Thyro... Sporadic Thyroi... Stage III Thyro... Stage IV Thyroi... Stage IVA Thyro... Stage IVB Thyro... Stage IVC Thyro...	Sorafenib Tosyl...	18 Years -	National Cancer Institute (NCI)
Carboplatin and Paclitaxel With or Without Sorafenib Tosylate in Treating Patients With Stage III or Stage IV Melanoma That Cannot Be Removed by Surgery	NCT00110019	Mucosal Melanom... Recurrent Melan... Stage IIIA Skin... Stage IIIB Skin... Stage IIIC Skin... Stage IV Skin M...	Carboplatin Laboratory Biom... Paclitaxel Pharmacological... Placebo Sorafenib Tosyl...	18 Years -	National Cancer Institute (NCI)
Sorafenib in Treating Patients With Stage IIIB or Stage IV Non-Small Cell Lung Cancer	NCT00098540	Recurrent Non-s... Stage IIIB Non-... Stage IV Non-sm...	sorafenib tosyl... laboratory biom...	18 Years -	National Cancer Institute (NCI)
Sorafenib Tosylate in Treating Patients With Locally Advanced, Metastatic, or Locally Recurrent Thyroid Cancer	NCT00095693	Anaplastic Thyr... Insular Thyroid... Recurrent Thyro... Stage III Folli... Stage III Papil... Stage IV Follic... Stage IV Papill...	sorafenib tosyl... laboratory biom... pharmacological... fludeoxyglucose... positron emissi... dynamic contras...	18 Years -	National Cancer Institute (NCI)
Sorafenib Tosylate and Chemoembolization in Treating Patients With Unresectable Liver Cancer	NCT01042041	Hepatocellular ... Liver Cancer Localized Unres...	sorafenib tosyl... doxorubicin hyd... cisplatin mitomycin C transarterial c... hepatic artery ...	18 Years -	Abramson Cancer Center at Penn Medicine
Sorafenib Tosylate in Treating Patients With Liver Cancer That Can Be Removed by Surgery	NCT01182272	Liver Cancer	sorafenib tosyl... laboratory biom... neoadjuvant the... therapeutic con...	18 Years -	National Cancer Institute (NCI)
Sorafenib and Isolated Limb Infusion of Melphalan in Treating Patients With Stage III Melanoma of the Arm or Leg	NCT00565968	Melanoma (Skin)	melphalan sorafenib tosyl... gene expression... protein express... western blottin... pharmacological...	18 Years -	Duke University
Sorafenib in Treating Patients With Stage III or Stage IV Melanoma That Cannot Be Removed By Surgery	NCT00119249	Stage III Melan... Stage IV Melano...	sorafenib tosyl... laboratory biom...	18 Years -	National Cancer Institute (NCI)

Take Control of Your Skin and Body Changes Today.

Try out Spots for free, set up only takes 2 mins.

Join others from around the world: